

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Harald Schmidt et al.)
Application No. 09/762,767)
Filed: June 1, 2001) Group Art Unit: 1652
For: ISOLATED AND PURIFIED HUMAN)
SOLUBLE GUANYLYLCYCLASE)
 $\alpha 1/\beta 1$ (hsGC $\alpha 1/\beta 1$))
Examiner: Manjunath N. Rao, Ph.D.) Attorney Docket No. VOS-101

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

OFFICIAL

FAX RECEIVED

JUN 17 2003

GROUP 1600

In response to the requirement for restriction set forth in the Office Action dated 20 May 2003 applicants provisionally elect for further prosecution at this time the claims of Group I, i.e., claims 1-8, inclusive, directed to isolated, soluble human guanylyl cyclase $\alpha 1/\beta 1$ and methods of producing same.

This election is made without traverse.

An early action on the merits is solicited.

Respectfully submitted,

June 16, 2003

OLSON & HIERL, LTD.
20 North Wacker Drive
36th Floor
Chicago, Illinois 60606
(312) 580-1180

By

Talivaldis Cepuritis (Reg. No. 20,818)

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this RESPONSE TO RESTRICTION REQUIREMENT is being transmitted by facsimile transmission to Examiner Manjunath N. Rao (Fax No. 703-308-4242) on June 16, 2003.

Talivaldis Cepuritis (Reg. No. 20,818)